Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-xL in addition to Bax and p53 status

被引:189
作者
Violette, S
Poulain, L
Dussaulx, E
Pepin, D
Faussat, AM
Chambaz, J
Lacorte, JM
Staedel, C
Lesuffleur, T [1 ]
机构
[1] Univ Paris 06, INSERM, U505, Paris, France
[2] CRLCC Francois Baclesse, UPRES EA 1772, Caen, France
[3] Hop Hotel Dieu, EPI 9912, F-75181 Paris, France
关键词
5-FU resistance; p53 and bax status; Bcl-2 and Bcl-x(L) expression; colon cancer cells;
D O I
10.1002/ijc.10146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Defects in apoptosis have been implicated in chemoresistance of colon cancer cells. We report here the ability to resist to 5-fluorouracil-induced apoptosis of 8 colon cancer cell lines differing in p53 and box status: p53(-/0)bax(+/+) for TC7, SW480, HT-29, pS3(+/+)bax(-/-) for LS174T, LoVo; p53(+/+) bax(+/-) for HCT116; p53(+/+) or p53(+/0)bax(+/+) for LS513 or HCT-EB, respectively. To approximate to the in vivo therapy, the cell lines were exposed to a long-term treatment of 5-FU. The analysis of proteins implicated in the apoptotic pathway has shown that the independent analysis of p53 or box status was not sufficient to predict the extent of drug-resistance of all cell lines. In p53(+/+) cell lines but not in p53(-/0) cell lines, a low level of the pro-apoptotic Bax protein was correlated with a greater resistance of cells to 5-FU. In addition, we found that high levels of anti-apoptotic Bcl-2 and Bcl-x(L) proteins combined with a low level of Bax were correlated to high 5-FU resistance of wild-type p53 cell lines. The same correlation was obtained for 2 out of 3 mutated p53 cell lines. In conclusion, the relative levels of Bcl-2, Bcl-x(L) and Bax may altogether contribute to determine the resistance of a majority of colon tumor cells to long-term 5-FU treatment, whatever their p53 status. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:498 / 504
页数:7
相关论文
共 41 条
[31]  
REED JC, 1997, APOPTOSIS CANC, P65
[32]   Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c [J].
Rossé, T ;
Olivier, R ;
Monney, L ;
Rager, M ;
Conus, S ;
Fellay, I ;
Jansen, B ;
Borner, C .
NATURE, 1998, 391 (6666) :496-499
[33]  
Schmoll HJ, 1999, SEMIN ONCOL, V26, P589
[34]   Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers [J].
Simms, LA ;
Radford-Smith, G ;
Biden, KG ;
Buttenshaw, R ;
Cummings, M ;
Jass, JR ;
Young, J ;
Meltzer, SJ ;
Leggett, BA .
ONCOGENE, 1998, 17 (15) :2003-2008
[35]   Pax can antagonize Bcl-X(L) during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-X(L) [J].
Simonian, PL ;
Grillot, DAM ;
Merino, R ;
Nunez, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (37) :22764-22772
[36]   The cellular response to p53: the decision between life and death [J].
Sionov, RV ;
Haupt, Y .
ONCOGENE, 1999, 18 (45) :6145-6157
[37]   Analysis of the p53/BAX pathway in colorectal cancer:: Low BAX is a negative prognostic factor in patients with resected liver metastases [J].
Sturm, I ;
Köhne, CH ;
Wolff, G ;
Petrowsky, H ;
Hillebrand, T ;
Hauptmann, S ;
Lorenz, M ;
Dörken, B ;
Daniel, PT .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1364-1374
[38]  
Wu YP, 1998, INT J ONCOL, V13, P1241
[39]  
Yang B, 1996, CLIN CANCER RES, V2, P1649
[40]   Role of BAX in the apoptotic response to anticancer agents [J].
Zhang, L ;
Yu, J ;
Park, BH ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 2000, 290 (5493) :989-+